Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05125029 · ClinicalTrials.gov registry record · Phase 4
Botulinum Toxin in Raynaud's Phenomenon
A Phase 4 study of Raynaud Phenomenon, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05125029: Recruiting Phase 4 study of Raynaud Phenomenon, sponsored by Emory University.
NCT05125029 is a Phase 4 study of Raynaud Phenomenon that is actively recruiting participants, run by Emory University. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05125029, a Phase 4 study of Raynaud Phenomenon, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.
Primary Outcome
Finger temperature measure of each finger on each hand was recorded on each digit before treatment and at the allotted follow-up intervals; the average of all digits on both hands was combined and recorded as the value for each point in data collection.
Conditions Studied
Interventions
- DRUG Botulinum toxin
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What NCT05125029 shows while recruiting
NCT05125029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Raynaud Phenomenon appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin is the first listed.
NCT05125029 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05125029 about?
NCT05125029 is a clinical study titled "Botulinum Toxin in Raynaud's Phenomenon". Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to e...
What is the current status of trial NCT05125029?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2022-02-10. Estimated completion is 2025-12.
What conditions does trial NCT05125029 study?
This clinical trial studies the following conditions: Raynaud Phenomenon.
What interventions are being tested in trial NCT05125029?
The interventions under investigation include: Botulinum toxin (DRUG).
Who is sponsoring clinical trial NCT05125029?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05125029 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05125029's enrollment target sits among peer trials
36 1490th of 2000 higher than 496 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI